Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism

Endocrine

Volumn 36, Issue 3, 2009, Pages 473-478

  Erem, Cihangir ^a   Ucuncu, Ozge ^a   Yilmaz, Mustafa ^a   Kocak, Mustafa ^a   Nuhoglu, Irfan ^a   Ersoz, Halil Onder ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Hemostasis; Hyperthyroidism; Thrombin activatable fibrinolysis inhibitor; Tissue factor pathway inhibitor

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 5; LIOTHYRONINE; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THYROID HORMONE; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GRAVES DISEASE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; THYROID HORMONE BLOOD LEVEL; TOXIC GOITER;

ADULT; BLOOD PRESSURE; CARBOXYPEPTIDASE U; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; GOITER, NODULAR; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; LIPOPROTEINS; MALE; MIDDLE AGED; RISK FACTORS; TRIIODOTHYRONINE; UP-REGULATION;

EID: 70449531380     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-009-9271-2     Document Type: Article

References (44)

1. C Erem HÖ Ersoz SS Karti K Ukinç A Hacihasanoǧlu O Deǧer M Telatar 2002 Blood coagulation and fibrinolysis in patients with hyperthyoidism J. Endocrinol. Invest. 25 345 350 1:CAS:528:DC%2BD38XktlWiu7o%3D 12030606
2. C Erem H Kavgaci HÖ Ersoz A Hacihasanoǧlu K Ukinç SS Karti O Deǧer M Telatar 2003 Blood coagulation and fibrinolytic activity in hypothyroidism Int. J. Clin. Pract. 57 78 81 1:STN:280:DC%2BD3s7ksF2qtw%3D%3D 12661786
3. C Erem 2006 Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity Clin. Endocrinol. 64 323 329 10.1111/j.1365-2265.2006.02464.x 1:CAS:528:DC%2BD28XjsFejsrk%3D
4. A Squizzato E Romualdi HR Büller VE Gerdes 2007 Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis:a systematic review J. Clin. Endocrinol. Metab. 92 2415 2420 10.1210/jc.2007-0199 1:CAS:528:DC%2BD2sXotVymu7g%3D 17440013 (Pubitemid 47037335)
5. M Franchini 2004 Hemostasis and thyroid diseases revisited J. Endocrinol. Invest. 27 886 892 1:STN:280:DC%2BD2M%2Fit1amsw%3D%3D 15648557
6. F Marongiu C Cauli S Mariotti 2004 Thyroid, hemostasis and thrombosis J. Endocrinol. Invest. 27 1065 1071 1:STN:280:DC%2BD2M7isVWisw%3D%3D 15754740
7. M Franchini 2006 Hemostatic changes in thyroid diseases Hematology 11 203 208 10.1080/10245330600667591 1:CAS:528:DC%2BD28Xht1SrurbE 17325963 (Pubitemid 44355703)
8. M Dorr DM Robinson H Wallaschofski C Schwahn U John SB Felix H Volzke 2006 Low serum thyrotropin is associated with high plasma fibrinogen J. Clin. Endocrinol. Metab. 91 530 534 10.1210/jc.2005-1786 16303831 (Pubitemid 43236922)
9. B Akinci A Comlekci S Yener T Demir MA Ozcan F Bayraktar S Yesil 2007 Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients Endocr. J. 54 593 599 10.1507/endocrj.K06-176 1:CAS:528: DC%2BD2sXhtlaqs7%2FP 17690487 (Pubitemid 47414608)
10. CF Presti RG Hart 1989 Thyrotoxicosis, atrial fibrillation, and embolism, revisited Am. Heart J. 117 976 977 10.1016/0002-8703(89)90642-X 1:STN:280:DyaL1M7ptVeksg%3D%3D 2929415 (Pubitemid 19097310)
11. J Burggraaf S Lalezari JJ Emeis UM Vischer PH de Meyer H Pijl AF Cohen 2001 Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol Thyroid 11 153 160 10.1089/ 105072501300042820 1:CAS:528:DC%2BD3MXlt1Gmsrw%3D 11288984
12. JS Rogers SR Shane FS Jencks 1982 Factor VIII activity and thyroid function Ann. Intern. Med. 97 713 716 6814317
13. F Marongiu M Conti G Mameli ML Murtas S Balzano G Sorano AM Mamusa E Martino 1988 Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment J. Endocrinol. Invest. 11 723 725 1:STN:280:DyaL1M7ls1agug%3D%3D 2466071
14. MA Ozcan A Comlekci F Demirkan F Yuksel I Sari T Demir GH Ozsan G Oruk S Yesil B Undar 2003 Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders Thromb. Res. 110 243 247 10.1016/S0049-3848(03)00408-0 1:CAS:528:DC%2BD3sXnsVKgsrg%3D 14512089 (Pubitemid 37338300)
15. E Rooth H Wallen A Antovic M von Arbin G Kaponides N Wahlgren M Blombäck J Antovic 2007 Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke Blood Coagul. Fibrinolysis 18 365 370 10.1097/MBC.0b013e3281139c34 1:CAS:528:DC%2BD2sXmvFGltbg%3D 17473579 (Pubitemid 46699415)
16. A Redlitz AK Tan DL Eaton EF Plow 1995 Plasma carboxypeptidases as regulators of the plasminogen system J. Clin. Invest. 96 2534 2538 10.1172/JCI118315 1:CAS:528:DyaK28XltF2ntw%3D%3D 7593646
17. NH van Tilburg FR Rosendaal RM Bertina 2000 Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis Blood 95 2855 2859 10779431
18. S Eichinger V Schönauer A Weltermann E Minar C Bialonczyk M Hirschl B Schneider P Quehenberger PA Kyrle 2004 Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism Blood 103 3773 3776 10.1182/blood-2003-10-3422 1:CAS:528:DC%2BD2cXjvF2iuro%3D 14739223 (Pubitemid 38596294)
19. FW Leebeek MP Goor AH Guimaraes GJ Brouwers MP Maat DW Dippel DC Rijken 2005 High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke J. Thromb. Haemost. 3 2211 2218 10.1111/j.1538-7836.2005.01484.x 1:CAS:528:DC%2BD2MXht1Gitb3I 16092924 (Pubitemid 41727199)
20. J Montaner M Ribó J Monasterio CA Molina J Alvarez-Sabín 2003 Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke Stroke 34 1038 1040 10.1161/01.STR.0000063139.06585.45 1:CAS:528:DC%2BD3sXitlyrt78%3D 12649517 (Pubitemid 36402986)
21. TM Ravindranath M Goto O Iqbal M Florian-Kujawski D Hoppensteadt R Hammadeh MM Sayeed J Fareed 2007 Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis Clin. Appl. Thromb. Hemost. 13 362 368 10.1177/1076029607305580 1:CAS:528: DC%2BD2sXhtFKisrrJ 17911187 (Pubitemid 350114524)
22. GJ Broze Jr 1992 The role of tissue factor pathway inhibitor in a revised coagulation cascade Semin. Hematol. 29 159 169 1:CAS:528:DyaK38XlvVylu7w%3D 1641662
23. T Abumiya T Yamaguchi T Terasaki T Kokawa K Kario H Kato 1995 Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients Thromb. Haemost. 74 1050 1054 1:CAS:528:DyaK2MXptVyiu7k%3D 8560412
24. M Kobayashi H Wada Y Wakita M Shimura T Nakase K Hiyoyama S Nagaya N Minami T Nakano H Shiku 1995 Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura Thromb. Haemost. 73 10 14 1:CAS:528:DyaK2MXjtFSktbc%3D 7740478
25. GM Harris CL Stendt BJ Vollenhoven TE Gan PG Tipping 1999 Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives Am. J. Hematol. 60 175 180 10.1002/(SICI)1096-8652(199903)60: 3<175::AID-AJH1>3.0.CO;2-X 1:CAS:528:DyaK1MXhvVGnu7w%3D 10072106 (Pubitemid 29108765)
26. LC Hofbauer AE Heufelder 1997 Coagulation disorders in thyroid diseases Eur. J. Endocrinol. 136 1 7 10.1530/eje.0.1360001 1:CAS:528:DyaK2sXhslGnsLY%3D 9037116
27. M Homoncik A Gessl A Ferlitsch B Jilma H Vierhapper 2007 Altered platelet plug formation in hyperthyroidism and hypothyroidism J. Clin. Endocrinol. Metab. 92 3006 3012 10.1210/jc.2006-2644 1:CAS:528:DC%2BD2sXptl2hsL0%3D 17488803 (Pubitemid 47236363)
28. JL Parker DH Lawson 1973 Death from thyrotoxicosis Lancet 2 894 895 10.1016/S0140-6736(73)92019-9 1:STN:280:DyaE2c%2FhsVeiug%3D%3D 4126930
29. A Squizzato VE Gerdes DP Brandjes HR Büller J Stam 2005 Thyroid diseases and cerebrovascular disease Stroke 36 2302 2310 10.1161/01.STR. 0000181772.78492.07 1:STN:280:DC%2BD2MrhvFyquw%3D%3D 16179578 (Pubitemid 41429267)
30. B Dahlback BO Villoutreix 2005 The anticoagulant protein C pathway FEBS Lett. 579 3310 3316 10.1016/j.febslet.2005.03.001 15943976 (Pubitemid 40804679)
31. ML Moster 2003 Coagulopathies and arterial stroke J. Neuroophthalmol. 23 63 71 12616091
32. B Dahlbäck 2000 Blood coagulation Lancet 355 1627 1632 10.1016/S0140-6736(00)02225-X 10821379
33. BA Lwaleed PS Bass 2006 Tissue factor pathway inhibitor: structure, biology and involvement in disease J. Pathol. 208 327 339 10.1002/path.1871 1:CAS:528:DC%2BD28XhvFOntb4%3D 16261634 (Pubitemid 43210519)
34. M Hoke PA Kyrle E Minar C Bialonzcyk M Hirschl B Schneider M Kollars A Weltermann S Eichinger 2005 Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism Thromb. Haemost. 94 787 790 16270631 (Pubitemid 41489238)
35. E Morishita T Hashimoto H Asakura M Saito M Yamazaki K Aoshima T Yoshida H Kato T Matsuda 1998 Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease Thromb. Haemost. 79 919 923 1:CAS:528:DyaK1cXivFyksrw%3D 9609221
36. J Monasterio P Bermúdez D Quiroga E Francisco B Meneses J Montaner 2003 Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study Pathophysiol. Haemost. Thromb. 33 382 386 10.1159/000083833 1:STN:280:DC%2BD2M%2FptVarsA%3D%3D 15692248 (Pubitemid 40278712)
37. L Bajzar R Manuel ME Nesheim 1995 Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor J. Biol. Chem. 270 14477 14484 10.1074/jbc.270.24.14477 1:CAS:528:DyaK2MXmsVSit7g%3D 7782309
38. I Juhan-Vague PE Morange H Aubert M Henry MF Aillaud MC Alessi A Samnegård E Hawe J Yudkin M Margaglione G Di Minno A Hamsten SE Humphries HIFMECH Study Group 2002 Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe Arterioscler. Thromb. Vasc. Biol. 22 867 873 10.1161/01.ATV.0000015445.22243.F4 1:CAS:528:DC%2BD38XjslGmu74%3D 12006404 (Pubitemid 34517803)
39. A Silveira K Schatteman F Goossens E Moor S Scharpé M Strömqvist D Hendriks A Hamsten 2000 Plasma procarboxypeptidase U in men with symptomatic coronary artery disease Thromb. Haemost. 84 364 368 1:CAS:528:DC%2BD3MXjtVOks7Y%3D 11019956
40. V Schroeder T Chatterjee H Mehta S Windecker T Pham N Devantay B Meier HP Kohler 2002 Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography Thromb. Haemost. 88 1020 1025 1:CAS:528:DC%2BD3sXisVWntg%3D%3D 12529754
41. HK Lau A Segev RA Hegele JD Sparkes JM Teitel RJ Chisholm BH Strauss 2003 Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis Thromb. Haemost. 90 1187 1191 1:CAS:528:DC%2BD3sXhtVWgsLbP 14652655
42. Santamaría A, Martínez-Rubio A, Borrell M, Mateo J, Ortín R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica. 2004; 89:880-81
43. C Erem O Ucuncu M Yilmaz M Kocak I Nuhoglu HO Ersoz 2009 Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism Endocrine 35 75 80 10.1007/s12020-008-9116-4 1:CAS:528:DC%2BD1MXhvVylt7s%3D 18958631
44. N Jayaprasad J Francis 2005 Atrial fibrillation and hyperthyroidism Indian Pacing Electrophysiol. J. 5 305 311